A fixed-dose combination (FDC) therapy primarily indicated for the management of painful diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor that addresses the underlying polyol pathway hyperactivity in diabetes. Methylcobalamin is a neurotropic form of Vitamin B12 that aids in nerve regeneration and myelin synthesis. Pregabalin is a calcium channel modulator that provides symptomatic relief from neuropathic pain by reducing neuronal hyperexcitability. This combination offers a multi-modal approach targeting both the pathophysiology and symptoms of diabetic neuropathy.
Adult: One tablet twice daily (after breakfast and dinner). The dose may be initiated at one tablet once daily for elderly or frail patients to improve tolerability.
Note: Tablets should be swallowed whole with a glass of water, with or without food (though taking Epalrestat before meals may be advised per some brands). Do not crush or chew. Maintain a consistent dosing schedule. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose.
The combination works via complementary mechanisms. Epalrestat inhibits aldose reductase, the first enzyme in the polyol pathway, reducing the accumulation of sorbitol and fructose within nerves, which is implicated in osmotic stress, oxidative damage, and reduced nerve conduction velocity in hyperglycemia. Methylcobalamin acts as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase, essential for nucleotide synthesis, neuronal repair, and myelin formation. It may also promote nerve regeneration. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters (e.g., glutamate, substance P, norepinephrine), thereby dampening hyperexcitability and providing analgesic, anxiolytic, and anticonvulsant effects.
Pregnancy: Pregnancy Category C (US FDA). Pregabalin: Animal studies showed teratogenicity. Epalrestat & Methylcobalamin: Insufficient data. Use only if potential benefit justifies potential risk to the fetus. Not recommended during pregnancy. Effective contraception advised for women of childbearing potential.
Driving: May impair ability to drive or operate machinery. Patients should not drive until they know how the medication affects them, especially during dose initiation and escalation. Dizziness and somnolence are common.
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive CNS depression (sedation, dizziness, respiratory depression). | Major |
| Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril, Enalapril) | Increased risk and severity of peripheral edema and angioedema. | Major |
| Thiazolidinediones (Pioglitazone, Rosiglitazone) | Increased risk of peripheral edema and weight gain. | Moderate |
| Levodopa | Methylcobalamin may reduce the efficacy of Levodopa in Parkinson's disease. | Moderate |
| Chloramphenicol | May antagonize the hematopoietic response to Methylcobalamin. | Moderate |
Same composition (Epalrestat (75mg) + Methylcobalamin (750mcg) + Pregabalin (75mg)), different brands: